Interferontherapie während der Entzugsbehandlung

Suchttherapie

Volumn 3, Issue , 2002, Pages

  Backmund, Markus ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

Detoxification Treatment; Hepatitis C; Intravenous Drug User; Opioid Dependency

Indexed keywords

EID: 8744298882     PISSN: 14399903     EISSN: 1439989X     Source Type: Journal    
DOI: 10.1055/s-2002-32770     Document Type: Article

References (36)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a c-DNA derived from a blood born non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362
2. Kelen GD, Green GB, Purcell RH, Chan DW, Qaqish BF, Siverstosn KT, Quinn TC. Hepatitis B and hepatitis C in emergency department patients. N Engl J Med 1992; 326: 1399–1404
3. Patti AM, Santi AL, Pompa MG, Giustini C, Vescia N, Mastroeni I, Fara GM. Viral hepatitis and drugs; a continuing problem. Int J Epidemiol 1993; 22: 135–139
4. Crofts N, Hooper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. MedjAust 1993; 159: 237–241
5. Coppola RC, Masia G, di Martino ML, Carboni G, Muggianu E, Piro R, Manconi P.E. Sexual behaviour and multiple infections in drug abusers. Eur J Epidemiol 1996; 12: 429–435
6. Diamantis I, Bassetti S, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997; 26: 794–797
7. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injecting drug users. J Acquir Immune Efic Syndr Hum Retroviral 1998; 18: US-19S(Suppl 1)
8. Gombas W, Fischer G, Jagsch R, Eder H, Okamoto I, Schindler S, Müller C, Ference P. Prevalence and distribution of Hepatitis C subtypes in patients with opioid depemdece. Eur Add Res 2000; 6: 198–204
9. Backmund M, Meyer K, von Zielonka M. Prävalenzdaten zu Hepatitis B und C bei Drogenabhängigen in München. Suchtmed 2001; 3: 21–24
10. Alter MJ, Kruszon-Moran D, Hainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562
11. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S (6B)
12. Alter MJ, Margolis HS, Krawczynski K. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899–1905
13. DiBisceghe AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969–974
14. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466
15. Seef LB. Natural history of hepatitis C. Hepatology 1997; 26 (Suppl 1): 21S-28S
16. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273–281
17. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus related cirrhosis. Hepatology 1998; 27: 1435–1440
18. Nishigucchi S, Shiomi S, Nakatani S, Takeda T et al. Prevention of hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Lancet 2001; 357: 196–197
19. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956–961
20. NIH-Management of hepatitis C. Vol. 15, no. 3 of NIH consensus statement. Bethesda, Md.: National Institutes of Health 1997
21. Morb Mortal Wkly Rep. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. 1998; 47: 1–39
22. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of Hepatitis C infection in injection drug users. Hepatology 2001; 34: 188–193
23. Kuo G, Choo QL, Alter HJ, Gitnick GT, Redeker AG, Purcelli RH, Miamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonno F, Colombo M, Lee WS, Kuo C, Berger K, Schuster JR, Overby LR, Bradley DW, Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244; 362–364
24. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570–583
25. Sarrazin U, Zeuzem S. Diagnostik der Hepatitis C. Suchtmed 2001; 3: 143–146
26. Backmund M. Suchttherapie. Landsberg/Lech: ecomed-verlag 1999
27. Backmund M, Meyer K, Eichenlaub D, Schutz CG. Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. Drug Alcohol Depend 2001; 64: 173–180
28. Backmund M, Eichenlaub D, Soyka M. Das Bundesmodellprojekt “Qualifizierte Entzugsbehandlung Drogenabhangiger” an einem Krankenhaus der Maximalversorgung: Konzept, Inanspruchnahme und klinische Ergebnisse. Gesundheitswesen 1998; 60: 552–557
29. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend 2000; 58: 85–92
30. Albanese AP, Gervitz C, Oppenheim B, Field JM, Abels I, Eustace JC. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD). J Addict Dis 2000; 19: 11–28
31. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154: 1121–1127
32. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treamtent. AIDS 2000; 14: 151–155
33. Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the sonsent process, and tetention of injection drug users recruited for an HIV vaccine tria. J Acquir Immune Defic Syndr Hum Retroviral 1995; 10: 386–390
34. Gourevtich MN, Wassermann W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996; 15: 93–104
35. Edhn BR, Seal KH, Lorvick J, Krai AH, Ciccarone DH, Moore LD, Lo B. Is it Justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211–214
36. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345: 215–217